acute graft versus host disease agvhd
Generon’s Recombinant IL-22 Receives US FDA Clearance For Phase IIa Trials
Following a successful Phase I study, Generon is moving its recombinant antibody F-652 to Phase IIa trials in collaboration with the Memorial Sloan-Kettering Cancer Center.



